Did You Know?

Editor’s Picks

Latest News

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as...

BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026

BH-30236 was generally well tolerated and demonstrated preliminary anti-leukemic activity, including in patients previously treated with venetoclax-based regimens, along with...

Bereaved Mothers Give a Gift to Every Grieving Father: The “All Fathers Day” Free Grief Support Bundle. A Documentary Film. A Live Father’s Day Support Group. Free Online Courses. A Dedicated Community. All Free. All at AllFathersDay.com

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary...

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents...

error: Content is protected !!